Author:
Chen Ying-Ying,Guo Wen-Juan,Shi Yan-Fen,Su Fei,Yu Fu-Huan,Chen Ru-Ao,Wang Chao,Liu Ji-Xi,Luo Jie,Tan Huang-Ying
Abstract
Abstract
Background
Type 1 gastric neuroendocrine tumors (NETs) are relatively rare to the extent that some physicians have little experience in diagnosing and treating them. The purpose of this study was to increase the understanding of the disease by analyzing and summarizing the management and prognoses of patients with type 1 gastric NETs at our center.
Methods
The data of 229 patients (59.4% female) with type 1 gastric NETs who were treated at our center during 2011–2022 were retrospectively analyzed.
Results
The average patient age was 50.5 ± 10.8 years. Multiple tumors affected 72.5% of the patients; 66.4% of the tumors were < 1 cm, 69.4% were NET G1, and 2.2% were stage III-IV. A total of 76.9% of the patients had received endoscopic management, 60.7% had received traditional Chinese medicine treatment, 10.5% received somatostatin analogues treatment, and 6.6% underwent surgical resection. Seventy patients (41.2%) experienced the first recurrence after a median follow-up of 31 months (range: 2-122 months), and the median recurrence-free time was 43 months. The 1-, 2-, and 3-year cumulative recurrence-free survival rates were 71.8%, 56.8%, and 50.3%, respectively. During a median follow-up of 39 months (range: 2-132 months), one patient had bilateral pulmonary metastasis, and no disease-related deaths were observed.
Conclusion
Type 1 gastric NETs have a high recurrence rate and a long disease course, underscoring the importance of long-term and comprehensive management.
Funder
National High Level Hospital Clinical Research Funding
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,General Medicine
Reference34 articles.
1. Rossi RE, Massironi S. The increasing incidence of neuroendocrine Neoplasms Worldwide: current knowledge and open issues. J Clin Med. 2022;11(13):3794.
2. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.
3. WHO Classification of Tumours Editorial Board. Digestive system tumours(5thed). WHO classification of tumours. Geneva:WHO: IARC Press; 2019. pp. 104–5.
4. Jiao X, Wang Z, Peng X, et al. Effects of Tumor types on treatment strategy formulation and prognostic evaluation of gastric neuroendocrine tumors. Future Oncol. 2020;16(28):2197–207.
5. Köseoğlu H, Duzenli T, Sezikli M. Gastric neuroendocrine Neoplasms: a review. World J Clin Cases. 2021;9(27):7973–85.